- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Mass Casualty Planning: Lessons Learned from Emergency Radiology
Dr. Susan Cross from Barts Health NHS Trust discusses the experiences of her institution with multiple mass casualty events during the American Society of Emergency Radiology 2020 annual meeting.
It is impossible to know when a major incident -- a multi-car crash, a subway attack, or even a major pandemic -- is going to strike. But, not knowing that it is coming does not mean radiology departments cannot be prepared.
In her session during the American Society of Emergency Radiology 2020 annual meeting, Dr. Susan Cross from Barts Health NHS Trust in London shared the experiences she and her emergency radiology colleagues have had in caring for patients impacted by multiple mass casualty events.
Cross spoke with Diagnostic Imaging and shared not only some lessons learned, but some details about modality-specific planning for these events, as well as what obstacles may exist.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room Podcast: Emerging Trends in the Radiology Workforce
February 11th 2022Richard Duszak, MD, and Mina Makary, MD, discuss a number of issues, ranging from demographic trends and NPRPs to physician burnout and medical student recruitment, that figure to impact the radiology workforce now and in the near future.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
